奈西立肽治疗急性心力衰竭的研究进展

严重心力衰竭时,可能存在内源性脑钠肽相对不足和/或脑钠肽抵抗。奈西立肽是重组人脑钠肽。国内外多项前瞻性临床研究均证实,奈西立肽能迅速改善急性心力衰竭患者的血流动力学状况和临床症状,其有效性和安全性明显优于常规静脉制剂。但是汇总分析发现奈西立肽有引起肾脏损害和死亡率增加的风险。因此临床医师在使用此药时应严格掌握临床适应证,同时需要进一步的临床研究明确奈西立肽在急性心力衰竭中的治疗地位。

Application of Nesiritide in acute heart failure

Severe heart failure may exist relative brain natriuretic peptide (BNP) deficiency and/or BNP resistance. Nesiritide is a recombinant human BNP (rhBNP). Several domestic and international prospective clinical studies have confirmed that Nesiritide can rapidly improve homodynamic status and clinical symptoms in patients with acute heart failure (AHF),and would offer a safer and more effective therapeutic option. But meta-analyses raised the question of safety with nesiritide therapy,specifically an increased risk of renal dysfunction and mortality. Future clinical trials will provide a better understanding of the role of nesiritide in the management of AHF.